{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:11:46Z","timestamp":1792059106148,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T00:00:00Z","timestamp":1477612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031283","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n\u2009=\u2009241) with reduced left ventricular ejection fraction (LVEF \u226445%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8\u2009mg once daily or matching placebo for 24\u2009weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7\u2009\u00b1\u20097.6% vs. 35.4\u2009\u00b1\u20099.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was \u22120.8% (\u22122.1, 0.5; P\u2009=\u20090.24). Heart rate increased with liraglutide [mean difference: 7\u2009b.p.m. (5, 9), P\u2009&amp;lt;\u20090.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P\u2009=\u20090.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.657","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T02:27:04Z","timestamp":1477621624000},"page":"69-77","source":"Crossref","is-referenced-by-count":572,"title":["Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)\u2014a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial"],"prefix":"10.1093","volume":"19","author":[{"given":"Anders","family":"Jorsal","sequence":"first","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Herlev University Hospital , Copenhagen ,","place":["Denmark"]},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"Holmager","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Herlev University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Stilling","family":"Tougaard","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"H\u00e4nselmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hvidovre University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Eifer","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Hjort","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Internal Medicine, Herlev University Hospital , Copenhagen ,","place":["Denmark"]},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Well\u00f8v","family":"Boesgaard","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center , Gentofte ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Videb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hvidovre University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Flyvbjerg","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Department of Endocrinology and Internal Medicine, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Wiggers","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Tarnow","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center , Gentofte ,","place":["Denmark"]},{"name":"Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Nordsj\u00e6llands University Hospital , Hiller\u00f8d ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"2026011721171657400_ejhf657-bib-0001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011721171657400_ejhf657-bib-0002","first-page":"2001","volume-title":"Lancet","author":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","year":"1999"},{"key":"2026011721171657400_ejhf657-bib-0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721171657400_ejhf657-bib-0004","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011721171657400_ejhf657-bib-0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2026011721171657400_ejhf657-bib-0006","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ Res"},{"key":"2026011721171657400_ejhf657-bib-0007","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am Heart J"},{"key":"2026011721171657400_ejhf657-bib-0008","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s12020-015-0798-0","article-title":"Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction","volume":"52","author":"Chen","year":"2016","journal-title":"Endocrine"},{"key":"2026011721171657400_ejhf657-bib-0009","doi-asserted-by":"crossref","first-page":"249827","DOI":"10.1155\/2012\/249827","article-title":"A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure","volume":"2012","author":"Munaf","year":"2012","journal-title":"Int J Pept"},{"key":"2026011721171657400_ejhf657-bib-0010","doi-asserted-by":"crossref","first-page":"H1096","DOI":"10.1152\/ajpheart.00930.2009","article-title":"Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure","volume":"298","author":"Halbirk","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721171657400_ejhf657-bib-0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004885","article-title":"A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)","volume":"4","author":"Jorsal","year":"2014","journal-title":"BMJ Open"},{"key":"2026011721171657400_ejhf657-bib-0012","first-page":"803","article-title":"Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011721171657400_ejhf657-bib-0013","first-page":"1143","article-title":"Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association","volume":"12","author":"Dickstein","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011721171657400_ejhf657-bib-0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjci\/jer316","article-title":"EAE\/ASE recommendations for image acquisition and display using three-dimensional echocardiography","volume":"13","author":"Lang","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026011721171657400_ejhf657-bib-0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/ejechocard\/jep188","article-title":"Reproducibility in echocardiographic assessment of the left ventricular global and regional function, the HUNT study","volume":"11","author":"Thorstensen","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"2026011721171657400_ejhf657-bib-0016","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"2026011721171657400_ejhf657-bib-0017","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026011721171657400_ejhf657-bib-0018","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"2026011721171657400_ejhf657-bib-0019","article-title":"Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD)","volume":"12","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011721171657400_ejhf657-bib-0020","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","article-title":"A Multicenter Observational Study of Incretin-based Drugs and Heart Failure","volume":"374","author":"Filion","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011721171657400_ejhf657-bib-0021","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2026011721171657400_ejhf657-bib-0022","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011721171657400_ejhf657-bib-0023","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide vs. sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"2026011721171657400_ejhf657-bib-0024","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc15-1437","article-title":"Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability","volume":"39","author":"Nakatani","year":"2016","journal-title":"Diabetes Care"},{"key":"2026011721171657400_ejhf657-bib-0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2026011721171657400_ejhf657-bib-0026","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2026011721171657400_ejhf657-bib-0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.peptides.2016.02.007","article-title":"Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes","volume":"78","author":"Huang","year":"2016","journal-title":"Peptides"},{"key":"2026011721171657400_ejhf657-bib-0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"2026011721171657400_ejhf657-bib-0029","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2026011721171657400_ejhf657-bib-0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Bohm","year":"2010","journal-title":"Lancet"},{"key":"2026011721171657400_ejhf657-bib-0031","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/eurjhf\/hft129","article-title":"Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties","volume":"16","author":"Dobre","year":"2014","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.657","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/1\/69\/66333034\/eurjhf_19_1_69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/1\/69\/66333034\/eurjhf_19_1_69.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:18:30Z","timestamp":1768702710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/1\/69\/8418993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,28]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.657","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1]]},"published":{"date-parts":[[2016,10,28]]}}}